Biotechnology company Moderna Inc (Nasdaq:MRNA) said on Tuesday that the European Medicines Agency (EMA) human medicines committee (CHMP) has started a rolling review of its vaccine candidate mRNA-1273 against COVID-19, based on its preclinical, clinical and CMC data and the confirmation of its eligibility of submission.
The independent, US NIH-appointed Data Safety Monitoring Board (DSMB) for the company's Phase 3 study of mRNA-1273 has informed Moderna that the COVE trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.
Under the COVE study, the company enrolled more than 30,000 participants in the US.
In conjunction, the COVE is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary